CN106214887A - A kind of can antitumor, improve immunity pharmaceutical composition - Google Patents
A kind of can antitumor, improve immunity pharmaceutical composition Download PDFInfo
- Publication number
- CN106214887A CN106214887A CN201610700822.XA CN201610700822A CN106214887A CN 106214887 A CN106214887 A CN 106214887A CN 201610700822 A CN201610700822 A CN 201610700822A CN 106214887 A CN106214887 A CN 106214887A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- antitumor
- agaricus blazei
- powder
- grifola frondosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 37
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 31
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 42
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 42
- 241001327634 Agaricus blazei Species 0.000 claims abstract description 40
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 13
- 206010003402 Arthropod sting Diseases 0.000 claims abstract description 10
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 9
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 63
- 239000000284 extract Substances 0.000 claims description 32
- 210000003022 colostrum Anatomy 0.000 claims description 29
- 235000021277 colostrum Nutrition 0.000 claims description 29
- 241000283690 Bos taurus Species 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 11
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
- 229920002752 Konjac Polymers 0.000 claims description 6
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 235000010485 konjac Nutrition 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims 1
- 229960000511 lactulose Drugs 0.000 claims 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims 1
- 230000000295 complement effect Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 25
- 238000002156 mixing Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 229920002472 Starch Polymers 0.000 description 18
- 239000008107 starch Substances 0.000 description 18
- 235000019698 starch Nutrition 0.000 description 18
- 239000011812 mixed powder Substances 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 210000001541 thymus gland Anatomy 0.000 description 16
- 239000002552 dosage form Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 239000008187 granular material Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000009835 boiling Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000000242 pagocytic effect Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 238000005202 decontamination Methods 0.000 description 9
- 230000003588 decontaminative effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000033065 inborn errors of immunity Diseases 0.000 description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 5
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000005498 polishing Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- -1 Remain 1/3 extractum Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 240000004904 Amorphophallus paeoniifolius Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of can antitumor, improve the pharmaceutical composition of immunity, this pharmaceutical composition includes following components: Rhizoma amorphophalli, Agaricus blazei Murrill, Grifola frondosa, beestings, oligosaccharide, ubiquinone10.The pharmaceutical composition of the present invention is by by several components compatibility scientifically and rationally, and these several components complement each other, it is possible to increase body immunity, simultaneously can also antitumor；And several component is dietotherapeutic, safe and reliable, have no side effect, and economical and practical.
Description
Technical field
The present invention relates to field of medicinal compositions, a kind of can antitumor, improve immunity pharmaceutical composition.
Background technology
Immunity is the defense mechanism of human body self, is human bioequivalence and any foreign body eliminating external intrusion (such as disease
Poison, antibacterial etc.), process aging, damage, dead, the own cells of degeneration, and identify and process vivo mutations cell and virus
The ability of infection cell, is human bioequivalence and the physiological reaction getting rid of " dissident ".In short, be exactly human body to the generation of disease or
The resistivity that the invasion of pathogen is had.Over the past thousands of years, the mankind are able to not only be suitable for existence at one but also be fraught with risks
In environment, survival has benefited from the protection of body immune barrier just." immune " word, sees ming dynasty of china medical book " immunity class the earliest
Side ", refer to " release epidemic disease ", namely prevent and treat the meaning of infectious disease." immune " word also have body from viral, badly outside
Ability at environment is looked like, it is possible to refer to spiritual resistance.
Modern medical science finds, immunity is a factor having substantial connection with aging, and immunocyte decline is old and feeble
One of most important reason.Some special cells of body immune system can by the antibacterial in invasion body, viral and internal
The cell of aging death, the cell suddenlyd change and cause the material of allergy, swallowed wholly and eliminated, thus being tieed up
Hold stablizing of internal milieu, keep body health.If because some reason makes immune system can not normally play protective effect, just
Easily cause the infection of the pathogen such as antibacterial, virus, fungus.Meanwhile, hypoimmunity also can promote human body " to monitor " that cell becomes
Different ability declines, and the cell development of canceration of leaving ultimately results in cancer.
The principal element of immunity degradation has: 1) age factor: life has the stage that two immunocompetences are low, i.e. child
Stage and old stage.The immune system of child is the most ripe, and function is unsound, hypoimmunity；And the biological organs of old man
Deterioration, acquisition nutritional capacity decline, and immune organ gradually atrophy decline, causes immunity degradation, on the other hand in addition
Should, child and old man are also the Liang Ge colonies that disease is occurred frequently.2) bad life style and custom: psychentonia, malnutrition,
Lack motion or do not have enough sleep, abuse of alcohol and smoking etc., all can suppress immune system, reduce immunity of organisms.3) other because of
Element: the antibiotic of noxious substance, some drugs, radiotherapy and excess in environment the most all can suppress immune system.
In the case of hypoimmunity, easily causing antibacterial, virus, fungus etc. and infect, therefore hypoimmunity is the most straight
The performance connect is exactly liable to illness.Frequent ill meeting increases the weight of the consumption of body, thus typically have a delicate constitution, malnutrition, essence
Dispirited, fatigue and weak, appetite reductions of god, sleep disorder etc. show, sick, having an injection to take medicine has become homely food.The most sick
Will be lot more time to recover, and usually recurrent exerbation.Health and intelligent development if things go on like this can be caused bad, be also easy to
Induction major disease.And when sick, it is necessary to take medicine.Medicine is respectively provided with certain toxic and side effects, the most often has an injection and eats
Medicine, its toxic and side effects is more difficult to avoid that.Meanwhile, often have an injection to take medicine and be also easy to make antibacterial to produce drug resistance, cause dual sense
Dye, makes health become worse.Therefore, in the case of hypoimmunity, have an injection to take medicine to have and cure the symptoms, not the disease, easily recur
Etc. shortcoming.Additionally, in the environment of same, somebody can be sick, and somebody is the safest and the most sound.Trace it to its cause, be because difference
The immunity of people different.
Accordingly, it would be desirable to a kind of product that can improve body immunity, be prevented effectively from the most sick, frequently have an injection and take medicine,
Cure the symptoms, not the disease, easily the problem of recurrence.
Summary of the invention
It is an object of the invention to provide a kind of can antitumor, improve immunity pharmaceutical composition.
For achieving the above object, the present invention uses herein below:
A kind of can antitumor, improve the pharmaceutical composition of immunity, this pharmaceutical composition includes following components: Rhizoma amorphophalli, a Ji
Tricholoma matsutake (lto et lmai) Singer, Grifola frondosa, beestings, oligosaccharide, ubiquinone10。
Further, described pharmaceutical composition in parts by weight, including following components: 1-90 part Rhizoma amorphophalli, 1-90 part Ji Song
Young pilose antler, 1-90 part Grifola frondosa, 1-90 part beestings, 1-90 part oligosaccharide, 0.001-5 part ubiquinone10。
Further, described Rhizoma amorphophalli includes but not limited to fresh konjak plant, Rhizoma amorphophalli dry product, Rhizoma amorphophalli extract, Rhizoma amorphophalli
The mixture of one or more in effective ingredient.The kind kind of Rhizoma amorphophalli does not limits, such as elephant-foot yam, white Rhizoma amorphophalli, bulbil konjak.
Further, described Agaricus blazei Murrill includes but not limited to fresh Agaricus blazei Murrill sporophore, is dried Agaricus blazei Murrill sporophore, fresh
Mycelium in Agaricus blazei Murill, the mixing of one or more being dried in Mycelium in Agaricus blazei Murill, Agaricus blazei Murrill extract, Agaricus blazei Murrill effective ingredient
Thing.
Further, described Grifola frondosa includes but not limited to fresh Grifola Frondosa sporophore, is dried Grifola Frondosa sporophore, fresh
Maitake mushroom mycelia, the mixing of one or more being dried in maitake mushroom mycelia, Effects of Extracts of Grifola frondosa on Active, Grifola frondosa effective ingredient
Thing.
Further, described beestings includes but not limited to fresh cattle colostrums, (i.e. cattle colostrums is done to be dried cattle colostrums
Powder), cattle colostrums powder extract, cattle colostrums powder effective ingredient, fresh beestings, in beestings effective ingredient
The mixture of one or more.
Further, described oligosaccharide includes but not limited to oligofructose, oligomeric galactose, oligomeric xylose, oligomeric breast fruit
The mixture of one or more in sugar, soybean oligo saccharide, inulin.
Further, described pharmaceutical composition in parts by weight, including following components: 1-90 part Rhizoma amorphophalli dry product, 1-90 part
Be dried Agaricus blazei Murrill sporophore, 1-90 part is dried Grifola Frondosa sporophore, 1-90 part cattle colostrums powder, 1-90 part oligofructose, 0.001-5
Part ubiquinone10。
Herein, " fresh " refers to the primary products without any artificial treatment." extract " refers to raw material through the most molten
The extract that agent obtains after extracting, extracting method does not limits, and can select this area conventional method as required." effective ingredient " i.e.
The composition in raw material, organism metabolism or chemical reaction worked.
Excipient can be added as required in aforesaid components composition.Described excipient includes but not limited to form sediment
Powder, sugar, water, ethanol, Mel, carboxymethyl starch sodium, microcrystalline Cellulose, spice, surfactant and mixture thereof.
The pharmaceutical composition of the present invention can make include but not limited to tablet, capsule, granule, buccal tablet, electuary,
The dosage forms such as pill, powder, solution, suspensoid, oral liquid, powder, externally-applied liniment, facial film.It is preferably made from capsule, sheet
Agent or granule.
The preparation method of the pharmaceutical composition of the present invention is different according to dosage form difference, including mixing after pulverizing, or
Person uses suitable reagent to mix after extracting, or uses suitable reagent to extract after mixing, and carries out routine according to required dosage form
Post processing.
The pharmaceutical composition of the present invention can be applied and include but not limited to medical treatment, disease-prevention or healthcare, beauty treatment, cosmetics etc.
Field.
The invention have the advantages that
The pharmaceutical composition of the present invention is for society's people's rhythm of life is fast now, operating pressure big, dietary structure does not conforms to
The features such as reason, environmental pollution, by by several components compatibility scientifically and rationally, these several components complement each other, by regulation machine
Internal secretion maintains internal function equilibrium, strengthening the body resistance, controls and supports combination, it is possible to increase body immunity, simultaneously can also antitumor；
And several component is dietotherapeutic, safe and reliable, have no side effect, and economical and practical, easy to carry, long-term taking can be bright
The aobvious immunity improving body, protects healthy, prevents exopathogen from invading, and reduces the probability that user catches, and improves raw
Bioplasm amount, improves work efficiency.There is life-time service safe and reliable, economical and practical feature, there is wide market prospect.
Detailed description of the invention
In order to be illustrated more clearly that the present invention, below in conjunction with preferred embodiment, the present invention is described further.Ability
Field technique personnel should be appreciated that following specifically described content is illustrative and be not restrictive, and should not limit this with this
The protection domain of invention.
Embodiment 1
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: Rhizoma amorphophalli powder 2
Part, Agaricus blazei Murrill (dry sporophore) 60 parts, Grifola frondosa (dry sporophore) 6 parts, cattle colostrums powder 3 parts, oligofructose 30 parts, ubiquinone10 3
Part and Polyethylene Glycol 5 parts.
The dosage form of embodiment 1 is decoction, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；By Agaricus blazei Murrill, Grifola frondosa decontamination, clean, put in container, add water
Not having immersion 30 minutes, and decocted to boiling with big fire, slow fire is endured 1 hour slowly afterwards, is leached by pan-fried juice；Add water, decoct with big fire
Boiling to boiling, slow fire is endured 1 hour slowly afterwards, is leached by pan-fried juice；Merge twice filtrate, when liquid temp to be filtered drops to 30-40 DEG C, add
Enter cattle colostrums powder, oligofructose, ubiquinone10, Polyethylene Glycol, stir, be eventually adding Rhizoma amorphophalli powder, stir,
Bag distribution packaging, obtains into packed decoction.
Embodiment 2
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: Rhizoma amorphophalli powder 80
Part, Agaricus blazei Murrill (dry sporophore) 8 parts, Grifola frondosa (dry sporophore) 60 parts, cattle colostrums powder 40 parts, oligofructose 3 parts, ubiquinone10 1
Part and starch 6 parts.
The dosage form of embodiment 2 is granule, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；Taking Agaricus blazei Murrill, Grifola frondosa decontamination, clean, per kilogram adds about
10L water, is heated to water boiling, decocts 2 hours, leach decocting liquid, extract 2 times altogether, after merging twice filtrate, and concentrating under reduced pressure, concentrate
To the extractum of relative density 1.10-1.20, take 2/3 extractum and be spray-dried at 120-180 DEG C, obtain extractum powder；By Rhizoma amorphophalli powder,
Cattle colostrums powder, oligofructose and ubiquinone10Mixing, pulverizes, and crosses 100 mesh sieves, obtains mixed-powder, standby；By extractum powder, remain
Yu 1/3 extractum, mixed-powder and starch mixing, pelletize, by particle packaging machine subpackage, obtain granule.
Embodiment 3
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: Rhizoma amorphophalli powder 60
Part, Agaricus blazei Murrill extract 30 parts, Effects of Extracts of Grifola frondosa on Active 30 parts, cattle colostrums powder 50 parts, oligofructose 40 parts, ubiquinone100.01 part,
Carboxymethyl starch sodium 6 parts and magnesium stearate 0.02 part.
The extraction process of Agaricus blazei Murrill extract:
Taking Agaricus blazei Murrill decontamination, clean, per kilogram adds about 10L water, is heated to water boiling, decocts 2 hours, leach pan-fried
Liquid, extracts 2 times altogether, after merging twice filtrate, and concentrating under reduced pressure, it is concentrated into the extractum of relative density 1.10-1.20, at 120-180
It is spray-dried at DEG C, obtains Agaricus blazei Murrill extract.
The extraction process of Effects of Extracts of Grifola frondosa on Active:
Taking Grifola frondosa decontamination, clean, per kilogram adds about 10L water, is heated to water boiling, decocts 2 hours, leach pan-fried
Liquid, extracts 2 times altogether, after merging twice filtrate, and concentrating under reduced pressure, it is concentrated into the extractum of relative density 1.10-1.20, at 120-180
It is spray-dried at DEG C, obtains Effects of Extracts of Grifola frondosa on Active.
The dosage form of embodiment 3 is tablet, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；By Rhizoma amorphophalli powder, oligofructose, cattle colostrums powder, ubiquinone10Mixing, pulverizes
Cross 100 mesh sieves, obtain mixed-powder；Agaricus blazei Murrill extract, Effects of Extracts of Grifola frondosa on Active, carboxymethyl starch sodium are mixed 30 minutes, then
Mixed-powder is added, continues mix homogeneously, make wetting agent with 60% ethanol solution afterwards, mixing, pelletize, be eventually adding tristearin
Acid magnesium, tabletting machine, obtain tablet.
Embodiment 4
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: Rhizoma amorphophalli powder 4
Part, Agaricus blazei Murrill (dry sporophore) 50 parts, Grifola frondosa (dry sporophore) 60 parts, cattle colostrums powder 60 parts, oligofructose 50 parts, ubiquinone10
2 parts and starch 4 parts.
The dosage form of embodiment 4 is capsule, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；Taking Agaricus blazei Murrill, Grifola frondosa, decontamination, clean, per kilogram adds about
10L water, is heated to water boiling, decocts 2 hours, leach decocting liquid, extract 2 times, after merging twice filtrate, be evaporated to the closeest
The extractum of degree 1.10-1.20, takes 2/3 extractum and is spray-dried at 120-180 DEG C, obtain extractum powder；By Rhizoma amorphophalli powder, cattle colostrums
Powder, oligofructose, ubiquinone10Mixing, pulverized 100 mesh sieves, obtained mixed-powder；By extractum powder, remain 1/3 extractum, mixing
Powder and starch mixing, pelletize, and fills capsule, polishing, obtains capsule.
Embodiment 5
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: konjaku powder
30 parts, Agaricus blazei Murrill (dry sporophore) 1 part, Grifola frondosa (dry sporophore) 89 parts, cattle colostrums powder 2 parts, oligofructose 90 parts, ubiquinone10
0.003 part and starch 10 parts.
The dosage form of embodiment 5 is granule, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；Taking Agaricus blazei Murrill, Grifola frondosa decontamination, clean, per kilogram adds about
10L water, is heated to water boiling, decocts 2 hours, leach decocting liquid, extract 2 times altogether, after merging twice filtrate, and concentrating under reduced pressure, concentrate
To the extractum of relative density 1.10-1.20, take 2/3 extractum and be spray-dried at 120-180 DEG C, obtain extractum powder；By Rhizoma amorphophalli essence
Powder, cattle colostrums powder, oligofructose and ubiquinone10Mixing, pulverizes, and crosses 100 mesh sieves, obtains mixed-powder, standby；By extractum powder,
Remain 1/3 extractum, mixed-powder and starch mixing, pelletize, by particle packaging machine subpackage, obtain granule.
Embodiment 6
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: konjaku powder
88 parts, Agaricus blazei Murrill extract 89 parts, Effects of Extracts of Grifola frondosa on Active 1 part, cattle colostrums powder 88 parts, oligomeric galactose 2 parts, ubiquinone105 parts,
Carboxymethyl starch sodium 5 parts.
The dosage form of embodiment 6 is granule, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；By konjaku powder, oligomeric galactose, cattle colostrums powder, ubiquinone10Mixing,
Pulverize 100 mesh sieves, obtain mixed-powder；Agaricus blazei Murrill extract, Effects of Extracts of Grifola frondosa on Active, carboxymethyl starch sodium are mixed 30 points
Clock, then mixed-powder is added, continue mix homogeneously, make wetting agent with 60% ethanol solution afterwards, mixing, pelletize, by granule
Racking machine subpackage, obtains granule.
Embodiment 7
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: Rhizoma amorphophalli powder 1
Part, Agaricus blazei Murrill (dry sporophore) 1 part, Grifola frondosa (dry sporophore) 80 parts, sheep colostrum powder 50 parts, oligomeric xylose 80 parts, ubiquinone10
4 parts and starch 6 parts.
The dosage form of embodiment 7 is capsule, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；Taking Agaricus blazei Murrill, Grifola frondosa, decontamination, clean, per kilogram adds about
10L water, is heated to water boiling, decocts 2 hours, leach decocting liquid, extract 2 times, after merging twice filtrate, be evaporated to the closeest
The extractum of degree 1.10-1.20, takes 2/3 extractum and is spray-dried at 120-180 DEG C, obtain extractum powder；By Rhizoma amorphophalli powder, goat's colostrum
Powder, oligomeric xylose, ubiquinone10Mixing, pulverized 100 mesh sieves, obtained mixed-powder；By extractum powder, remain 1/3 extractum, mixing
Powder and starch mixing, pelletize, and fills capsule, polishing, obtains capsule.
Curative effect evaluation of the present invention is tested:
Test: are improved immunity by animal for the sample using the embodiment of the present invention to prepare and anti-tumor in vivo carries out effect and comments
Estimate.
L materials and methods
1.1 animals and tumor strain
Kunming kind healthy mice, weight 18-22g, 6-8 week old, male and female dual-purpose；
Transplanted tumor S180Ascitic type mice.
1.2 materials and reagent
The sample (being configured to test desired concn solution, 2mg/ml) that embodiment 2 prepares；
India ink；
Phosphate buffer (PBS): containing 8gNaCl, 0.2g KCl, 1.44g Na2HPO4、0.24g KH2PO4、1000ml
H2O。
1.3 instrument and equipment
Single beam ultraviolet-visible spectrophotometer；
Electronic analytical balance.
1, the sample of embodiments of the invention is on mouse immune organ thymus and the impact of index and spleen index
Take mice 24, male and female half and half, be randomly divided into 2 groups, i.e. normal saline group and sample sets.Often group 12.Each group is all
By 10ml/kg gastric infusion, once a day, continuous 10d.Mice ad lib and drinking-water.
12h after last administration, de-cervical vertebra is put to death mice and is also dissected, take out thymus, spleen, suck surface bloodstain, uses
Analytical balance claims its quality, by formula (l) calculating thymus and index and spleen index:
The weight (g) (1) of quality (the mg)/mice of thymus (or spleen) index (mg/g)=internal organs
The results are shown in Table 1.
The impact (X ± s, n=12) on mouse immune organ thymus and index and spleen index of table 1 sample
| Group | Thymus index (mg/g) | Thymus rate of increase | Index and spleen index (mg/g) | Spleen rate of increase |
| Normal saline group | 2.65±0.23 | 9.43±0.43 | ||
| Sample sets | 3.68±0.16* | 38.9% | 12.16±0.68* | 29.0% |
Note: compare with normal saline group, * represents P < 0.05.
2, mice reticuloendothelial system phagocytic is cleaned up inertia carbon granules ability in blood flow by the sample of embodiments of the invention
Impact
Take kunming mice 24, weight 18-22g, male, it is randomly divided into 2 groups, i.e. normal saline group and sample sets.Often
Organize 12.Respectively organize all by 10ml/kg gastric infusion, once a day, continuous 10d.Mice ad lib and drinking-water.
After last is administered 24h, the india ink 10ml/kg of mouse tail vein injection 4 times dilution, clocking immediately, (injection is not
Winner gives up), 1min and 10min after injection prepared Chinese ink, take a blood sample under mice socket of the eye 0.05ml, is blown into 4ml 0.1%Na2CO3
In solution.De-cervical vertebra puts to death mice, takes liver, spleen and thymus, claims its quality with analytical balance, by the Na of haemolysis2CO3Solution
Shake up, at 675nm wavelength, carry out colorimetric. record absorbance λ, calculate phagocytic index k according to formula (2), gulp down according to formula (3) calculating
Bite coefficient (correction phagocytosis is given advice) α and calculate the rate of increase of each index by formula (4):
K=(lgc1-lgc2)/(t1-t2) (2)
Rate of increase %=[sample sets phagocytic index (or coefficient) normal saline group phagocytic index (or coefficient)]/physiology salt
Water group phagocytic index (or coefficient) × 100 (4)
T in formula1、t2Represent respectively and inject prepared Chinese ink 1min and 10min；c1、c2Represent t1、t2In moment blood, carbon granules is dense
Degree；M represents weight g；m1Represent liver spleen and thymus gross mass g.
Medication group is compared with matched group, the results are shown in Table 2.
Mice reticuloendothelial system phagocytic is cleaned up impact (X ± s, the n=of inertia carbon granules ability in blood flow by table 2 sample
12)
| Group | Number of cases | Phagocytic index k | Phagocytic index rate of increase | Phagocytosis factor alpha | Phagocytosis coefficient rate of increase |
| Normal saline group | 11 | 0.0255±0.0076 | 4.3365±0.5787 | ||
| Sample sets | 10 | 0.0342±0.0065* | 34.1% | 5.4657±0.4185* | 26.0% |
Note: compare with normal saline group, * represents P < 0.05.
3, the anti-tumor in vivo test of the sample of embodiments of the invention
Mice S180Lotus tumor model set up S180Cell, after Secondary Culture, collects cell in the exponential phase of growth of cell,
It is centrifuged 5min in 1000r/min, washs 2 times with PBS, be centrifuged and remove supernatant, dilute with physiological saline solution, adjust cell quantity
To (2-3) × 106ml‐1, randomly select 5 healthy mices, every above-mentioned cell suspension of lumbar injection 0.5ml, notice that observation connects
Plant the ascites growing state of mice.
After about one week, the abdominal part of Mice Inoculated substantially swells, protrudes, aseptic aspiration ascites, and ascites is creamy white, slightly muddy.
With physiological saline solution with the dilution proportion of 1:2 in sterile test tube, with above-mentioned ascites dilutions, mice is inoculated, every
Mice right fore axil subcutaneous vaccination 0.2ml diluent.
It is i.e. normal saline group and sample sets by mice random packet.Often group 12.After inoculation in 24h gavage, continuously
10d.Mice ad lib and drinking-water.
After drug withdrawal 24h, de-cervical vertebra puts to death mice, carefully after sterilization skin, carefully cuts tumor surface skin, fully exposes
Tumor mass tissue, carefully peels off tumor tissues along tumor capsule. the tumor mass peeled is placed on sterile gauze around exhaustion tumor mass residual
Stagnant blood mark, weighs and records tumor weight.Calculate inhibition rate of tumor growth according to the following formula:
Inhibition rate of tumor growth %=(the average tumor of matched group weighs an administration group average tumor weight)/matched group average tumor weight ×
100
The results are shown in Table 3.
To S in table 3 sample bodyl80The impact (X ± s, n=12) of mice with tumor growth
| Group | Before administration (only) | After administration (only) | Body weight gains (g) | Average tumor weight (mg) | Tumour inhibiting rate | Remarks |
| Normal saline group | 12 | 11 | 7.5±0.43 | 1.83±0.25 | Dead one | |
| Sample sets | 12 | 12 | 7.5±0.45 | 1.01±0.13* | 44.81% |
Note: compare with normal saline group, * represents P < 0.05.
This laboratory observation sample is to mouse immune shoot formation, reticuloendothelial system phagocytic function and in vivo anti-swollen
The impact of tumor activity.
Result shows, to mouse stomach sample 20mg/ (kg*d), continuous 10d.The sample of the present invention can promote mouse thymus
Propagation with spleen；Mice reticuloendothelial system phagocytic can be improved and process the ability of inertia carbon granules in blood flow；To S180Mice with tumor
There is extremely significantly Anticancer effect in vivo.Above-mentioned impact and matched group (normal saline group) have significant difference, reflect this
The sample of invention all has potentiation to the non-specific immunity of mice with specific immune function.
From the experimental results, the pharmaceutical composition of the present invention has: promote mouse thymus and the propagation of spleen；Improve mice
Reticuloendothelial system phagocytic processes the ability of inertia carbon granules in blood flow；With to S180Mice with tumor has extremely significantly anti-tumor in vivo
Effect.Non-specific immunity and specific immune function to mice all have potentiation.It can be assumed that the group of the present invention
Compound has antitumor, improves the effect of immunity.
Comparative example 1
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: Rhizoma amorphophalli powder 80
Part, Grifola frondosa (dry sporophore) 60 parts, cattle colostrums powder 40 parts, oligofructose 3 parts, ubiquinone101 part and starch 6 parts.
The dosage form of comparative example 1 is granule, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；Taking Grifola frondosa decontamination, clean, per kilogram adds about 10L water, adds
Heat is seethed with excitement to water, decocts 2 hours, leaches decocting liquid, extracts 2 times altogether, after merging twice filtrate, and concentrating under reduced pressure, it is concentrated into the closeest
The extractum of degree 1.10-1.20, takes 2/3 extractum and is spray-dried at 120-180 DEG C, obtain extractum powder；By Rhizoma amorphophalli powder, cattle colostrums
Powder, oligofructose and ubiquinone10Mixing, pulverizes, and crosses 100 mesh sieves, obtains mixed-powder, standby；By extractum powder, residue 1/3 leaching
Cream, mixed-powder and starch mixing, pelletize, by particle packaging machine subpackage, obtain granule.
Comparative example 2
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: Rhizoma amorphophalli powder 60
Part, Agaricus blazei Murrill extract 30 parts, cattle colostrums powder 50 parts, oligofructose 40 parts, ubiquinone100.01 part, carboxymethyl starch sodium 6 parts and
Magnesium stearate 0.02 part.
The dosage form of comparative example 2 is tablet, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；By Rhizoma amorphophalli powder, oligofructose, cattle colostrums powder, ubiquinone10Mixing, pulverizes
Cross 100 mesh sieves, obtain mixed-powder；Agaricus blazei Murrill extract, carboxymethyl starch sodium are mixed 30 minutes, then added by mixed-powder
Enter, continue mix homogeneously, make wetting agent with 60% ethanol solution afterwards, mixing, pelletize, be eventually adding magnesium stearate, tablet machine
Tabletting, obtains tablet.
Comparative example 3
A kind of can antitumor, improve immunity pharmaceutical composition, in parts by weight, including following components: Rhizoma amorphophalli powder 4
Part, Agaricus blazei Murrill (dry sporophore) 50 parts, Grifola frondosa (dry sporophore) 60 parts, oligofructose 50 parts, ubiquinone102 parts and starch 4
Part.
The dosage form of comparative example 3 is capsule, and preparation method is as follows:
Each raw material components is weighed by above-mentioned weight portion；Taking Agaricus blazei Murrill, Grifola frondosa, decontamination, clean, per kilogram adds about
10L water, is heated to water boiling, decocts 2 hours, leach decocting liquid, extract 2 times, after merging twice filtrate, be evaporated to the closeest
The extractum of degree 1.10-1.20, takes 2/3 extractum and is spray-dried at 120-180 DEG C, obtain extractum powder；By Rhizoma amorphophalli powder, oligomeric fruit
Sugar, ubiquinone10Mixing, pulverized 100 mesh sieves, obtained mixed-powder；By extractum powder, remain 1/3 extractum, mixed-powder and shallow lake
Powder mixes, and pelletizes, and fills capsule, polishing, obtains capsule.
According to aforesaid experimental technique, the sample that comparative example 1 prepares is tested it mouse immune organ thymus and spleen are referred to
The impact of number, the results are shown in Table 4.
The impact (X ± s, n=12) on mouse immune organ thymus and index and spleen index of the table 4 each sample group
| Group | Thymus index (mg/g) | Thymus rate of increase | Index and spleen index (mg/g) | Spleen rate of increase |
| Normal saline group | 2.65±0.23 | 9.43±0.43 | ||
| Comparative example group | 3.06±0.21* | 15.5% | 10.05±0.48* | 6.6% |
| Embodiment sample sets | 3.68±0.16* | 38.9% | 12.16±0.68* | 29.0% |
Visible, the thymus rate of increase of the sample of comparative example and spleen rate of increase are all far below the sample of the present invention.
The compositions that six kinds of components that the present invention is found by great many of experiments compound can be tieed up by regulation organism endocrine
Hold internal function equilibrium, it is possible to increase body immunity, simultaneously can also antitumor.
Obviously, the above embodiment of the present invention is only for clearly demonstrating example of the present invention, and is not right
The restriction of embodiments of the present invention, for those of ordinary skill in the field, the most also may be used
To make other changes in different forms, cannot all of embodiment be given exhaustive here, every belong to this
What bright technical scheme was extended out obviously changes or changes the row still in protection scope of the present invention.
Claims (8)
1. one kind can antitumor, improve immunity pharmaceutical composition, it is characterised in that described pharmaceutical composition includes following group
Point: Rhizoma amorphophalli, Agaricus blazei Murrill, Grifola frondosa, beestings, oligosaccharide, ubiquinone10。
The most according to claim 1 a kind of can antitumor, improve immunity pharmaceutical composition, it is characterised in that described
Pharmaceutical composition in parts by weight, including following components: 1-90 part Rhizoma amorphophalli, 1-90 part Agaricus blazei Murrill, 1-90 part Grifola frondosa, 1-90 part
Beestings, 1-90 part oligosaccharide, 0.001-5 part ubiquinone10。
The most according to claim 1 a kind of can antitumor, improve immunity pharmaceutical composition, it is characterised in that described
Rhizoma amorphophalli is the mixture of one or more in fresh konjak plant, Rhizoma amorphophalli dry product, Rhizoma amorphophalli extract, Rhizoma amorphophalli effective ingredient.
The most according to claim 1 a kind of can antitumor, improve immunity pharmaceutical composition, it is characterised in that described
Agaricus blazei Murrill be fresh Agaricus blazei Murrill sporophore, be dried Agaricus blazei Murrill sporophore, fresh Mycelium in Agaricus blazei Murill, be dried Mycelium in Agaricus blazei Murill,
The mixture of one or more in Agaricus blazei Murrill extract, Agaricus blazei Murrill effective ingredient.
The most according to claim 1 a kind of can antitumor, improve immunity pharmaceutical composition, it is characterised in that described
Grifola frondosa be fresh Grifola Frondosa sporophore, be dried Grifola Frondosa sporophore, fresh maitake mushroom mycelia, be dried maitake mushroom mycelia,
The mixture of one or more in Effects of Extracts of Grifola frondosa on Active, Grifola frondosa effective ingredient.
The most according to claim 1 a kind of can antitumor, improve immunity pharmaceutical composition, it is characterised in that described
Beestings is fresh cattle colostrums, is dried cattle colostrums, cattle colostrums powder extract, cattle colostrums powder effective ingredient, fresh suckling
The mixture of one or more in animal foremilk, beestings effective ingredient.
The most according to claim 1 a kind of can antitumor, improve immunity pharmaceutical composition, it is characterised in that described
Oligosaccharide is one or more in oligofructose, oligomeric galactose, oligomeric xylose, oligomeric lactulose, soybean oligo saccharide, inulin
Mixture.
The most according to claim 1 a kind of can antitumor, improve immunity pharmaceutical composition, it is characterised in that described
Pharmaceutical composition in parts by weight, including following components: 1-90 part Rhizoma amorphophalli dry product, 1-90 part are dried Agaricus blazei Murrill sporophore, 1-90
Part dry Grifola Frondosa sporophore, 1-90 part cattle colostrums powder, 1-90 part oligofructose, 0.001-5 part ubiquinone10。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610700822.XA CN106214887A (en) | 2016-08-22 | 2016-08-22 | A kind of can antitumor, improve immunity pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610700822.XA CN106214887A (en) | 2016-08-22 | 2016-08-22 | A kind of can antitumor, improve immunity pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106214887A true CN106214887A (en) | 2016-12-14 |
Family
ID=57554318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610700822.XA Pending CN106214887A (en) | 2016-08-22 | 2016-08-22 | A kind of can antitumor, improve immunity pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106214887A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111329968A (en) * | 2020-03-27 | 2020-06-26 | 潍坊峰林功能食品技术研究院有限公司 | Selenium-enriched agaricus blazei murill and ash tree flower tablet and preparation method thereof |
| CN111407850A (en) * | 2020-05-08 | 2020-07-14 | 潍坊峰林功能食品技术研究院有限公司 | Plant selenium sealwort tablet and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101305793A (en) * | 2007-05-17 | 2008-11-19 | 沙纯荣 | Grifola frondosa edible and medicinal fungi |
| CN101971961A (en) * | 2010-09-10 | 2011-02-16 | 江苏安惠生物科技有限公司 | Sugar substitute prepared from polysaccharides of edible fungi and dietary fiber and production method thereof |
| CN102178699A (en) * | 2011-04-20 | 2011-09-14 | 威海康博尔生物药业有限公司 | Preparation for enhancing human immunity and promoting growth and development |
| CN104397535A (en) * | 2014-12-05 | 2015-03-11 | 黑龙江众生生物工程有限公司 | Composite edible-medicinal fungal oral liquid for enhancing immunity and production method for composite edible-medicinal fungal oral liquid |
-
2016
- 2016-08-22 CN CN201610700822.XA patent/CN106214887A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101305793A (en) * | 2007-05-17 | 2008-11-19 | 沙纯荣 | Grifola frondosa edible and medicinal fungi |
| CN101971961A (en) * | 2010-09-10 | 2011-02-16 | 江苏安惠生物科技有限公司 | Sugar substitute prepared from polysaccharides of edible fungi and dietary fiber and production method thereof |
| CN102178699A (en) * | 2011-04-20 | 2011-09-14 | 威海康博尔生物药业有限公司 | Preparation for enhancing human immunity and promoting growth and development |
| CN104397535A (en) * | 2014-12-05 | 2015-03-11 | 黑龙江众生生物工程有限公司 | Composite edible-medicinal fungal oral liquid for enhancing immunity and production method for composite edible-medicinal fungal oral liquid |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111329968A (en) * | 2020-03-27 | 2020-06-26 | 潍坊峰林功能食品技术研究院有限公司 | Selenium-enriched agaricus blazei murill and ash tree flower tablet and preparation method thereof |
| CN111407850A (en) * | 2020-05-08 | 2020-07-14 | 潍坊峰林功能食品技术研究院有限公司 | Plant selenium sealwort tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6305407B2 (en) | Chinese medicine composition for regulating immunity and method for producing the same | |
| JP6305457B2 (en) | Application of herbal medicine composition to the preparation of health foods and medicines for the relief and prevention treatment of physical fatigue | |
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| US11931389B2 (en) | Tablet of sporoderm-removed ganoderma lucidum spore and preparation method thereof | |
| CN101987169A (en) | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus | |
| CN102600212B (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN111264862A (en) | Anti-fatigue composition, preparation method thereof and anti-fatigue medicine or health food | |
| CN109316491A (en) | NK cell combines application of the mescenchymal stem cell in treatment hepatitis and liver fibrosis | |
| CN103169737B (en) | Composite of Antrodia camphorata entity and shell-broken ganoderma lucidum spore powder and application thereof in immune adjustment | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN106820151A (en) | A kind of bivalve compound health composition, preparation method and application | |
| CN106214887A (en) | A kind of can antitumor, improve immunity pharmaceutical composition | |
| CN100496536C (en) | Alpha-glucosidase activity inhibitor | |
| CN102319379A (en) | Formula for treating and preventing cancerous tumors and preparation and production process of Chinese caterpillar fungus tumor rehabilitation oral liquid | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN107951992A (en) | A kind of Chinese medicine composition for strengthen immunity and preparation method thereof | |
| CN102885305A (en) | Health food composition for enhancing immunity and preparation method thereof | |
| CN107536016B (en) | A nutritional food for protecting heart and promoting liver health | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN101721612A (en) | Chinese medicinal composition for raising leucocytes and preparation method and application thereof | |
| CN105998098A (en) | Method for preparing traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN101283996A (en) | Application of D-methionine in preparation of drugs for prevention and treatment of radiation-induced myelosuppression | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN1854148A (en) | Astragaloside extract and preparation method thereof | |
| JPH10306033A (en) | Nontoxic and completely natural anticancer agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |